Jonathan L Wright1, Daniel W Lin, Janet L Stanford. 1. Department of Urology, University of Washington School of Medicine, Seattle, Washington 98195, USA. jlwright@u.washington.edu
Abstract
INTRODUCTION: Studies have reported lower prostate specific antigen (PSA) levels in men with a higher body mass index (BMI). Additional factors such as diabetes mellitus, benign prostatic hyperplasia (BPH) and certain medications may also affect PSA levels and confound the PSA-BMI association. In this study we evaluated the potential confounding effect of these factors on the obesity-PSA relationship and evaluated the association between these factors and PSA level. METHODS: The study cohort consisted of 770 population-based controls without a history of prostate cancer (PCa) who participated in a prior PCa study. Demographic, anthropometric, and medical history data were obtained, and PSA level was determined from blood drawn at the time of interview. Linear regression was performed to evaluate the PSA-BMI relationship, adjusting for potential confounders. Finally, a forward stepwise algorithm was used to determine which factors were independently associated with PSA values. RESULTS: With increase in BMI (<25, 25-29, ≥30), the geometric mean PSA level declined (1.18, 1.13, and 0.94, respectively); obese men had a 17% (95% CI 0.70-0.99) lower age-adjusted PSA level compared to normal weight men. However, this relationship was non-significant (P = 0.17) in the multivariate model. Independent predictors of PSA level included age (β = 1.03, 95% CI 1.02-1.04), history of BPH (β = 1.48, 95% CI 1.27-1.72), current statin (β = 0.85, 95% CI 0.74-0.98), and NSAID use (β = 0.84, 95% CI 0.72-0.98). CONCLUSION: The relationship between obesity and PSA is confounded by a number of factors, which likely explain the observed inverse association previously reported. These results should help in interpreting PSA values in men screened for PCa.
INTRODUCTION: Studies have reported lower prostate specific antigen (PSA) levels in men with a higher body mass index (BMI). Additional factors such as diabetes mellitus, benign prostatic hyperplasia (BPH) and certain medications may also affect PSA levels and confound the PSA-BMI association. In this study we evaluated the potential confounding effect of these factors on the obesity-PSA relationship and evaluated the association between these factors and PSA level. METHODS: The study cohort consisted of 770 population-based controls without a history of prostate cancer (PCa) who participated in a prior PCa study. Demographic, anthropometric, and medical history data were obtained, and PSA level was determined from blood drawn at the time of interview. Linear regression was performed to evaluate the PSA-BMI relationship, adjusting for potential confounders. Finally, a forward stepwise algorithm was used to determine which factors were independently associated with PSA values. RESULTS: With increase in BMI (<25, 25-29, ≥30), the geometric mean PSA level declined (1.18, 1.13, and 0.94, respectively); obesemen had a 17% (95% CI 0.70-0.99) lower age-adjusted PSA level compared to normal weight men. However, this relationship was non-significant (P = 0.17) in the multivariate model. Independent predictors of PSA level included age (β = 1.03, 95% CI 1.02-1.04), history of BPH (β = 1.48, 95% CI 1.27-1.72), current statin (β = 0.85, 95% CI 0.74-0.98), and NSAID use (β = 0.84, 95% CI 0.72-0.98). CONCLUSION: The relationship between obesity and PSA is confounded by a number of factors, which likely explain the observed inverse association previously reported. These results should help in interpreting PSA values in men screened for PCa.
Authors: Rosebud O Roberts; Debra J Jacobson; Cynthia J Girman; Thomas Rhodes; Michael M Lieber; Steven J Jacobsen Journal: Mayo Clin Proc Date: 2002-03 Impact factor: 7.616
Authors: Jay H Fowke; Saundra S Motley; Daniel A Barocas; Michael S Cookson; Raoul Concepcion; Susan Byerly; Joseph A Smith Journal: Cancer Causes Control Date: 2010-12-19 Impact factor: 2.506
Authors: Stacy Loeb; H Ballentine Carter; Edward M Schaeffer; Luigi Ferrucci; Anna Kettermann; E Jeffrey Metter Journal: J Urol Date: 2009-12 Impact factor: 7.450
Authors: Jay H Fowke; Saundra S Motley; Joseph A Smith; Michael S Cookson; Raoul Concepcion; Sam S Chang; Susan Byerly Journal: J Urol Date: 2009-03-14 Impact factor: 7.450
Authors: Robert L Grubb; Amanda Black; Grant Izmirlian; Thomas P Hickey; Paul F Pinsky; Jerome E Mabie; Thomas L Riley; Lawrence R Ragard; Philip C Prorok; Christine D Berg; E David Crawford; Timothy R Church; Gerald L Andriole Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-03-03 Impact factor: 4.254
Authors: J Curtis Nickel; Akira Furuta; Michael B Chancellor; Claus G Roehrborn; Dean G Assimos; Ellen Shapiro; Michael K Brawer Journal: Rev Urol Date: 2010
Authors: Sean Harrison; Kate Tilling; Emma L Turner; J Athene Lane; Andrew Simpkin; Michael Davis; Jenny Donovan; Freddie C Hamdy; David E Neal; Richard M Martin Journal: Cancer Causes Control Date: 2016-11-09 Impact factor: 2.506
Authors: Kerri Beckmann; Danielle Crawley; Tobias Nordström; Markus Aly; Henrik Olsson; Anna Lantz; Noor Binti Abd Jalal; Hans Garmo; Jan Adolfsson; Martin Eklund; Mieke Van Hemelrijck Journal: JAMA Netw Open Date: 2019-11-01